Abstract:Obesity is the global epidemic of the 21st century: about 1.5 billion adults worldwide are overweight, and among them, about 200 million men and 300 million women are obese. The prevalence of overweight and obesity is also increasing in children and adolescents in developed (about 25%) and developing countries (about 13%). Obesity has been associated with many comorbidities, including type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), hypertension, chronic kidney disease, cardiovascular disease (CVD), and malignancies, leading to increased mortality observed in obese individuals. Overweight and obesity were estimated to be associated worldwide with 3.4 million deaths, which could also be expressed as 4% of disability-adjusted life-years lost (DALYs). It is also alarming that children with severe obesity are apparently at in- creased risk of premature death. Managing obesity is hard and usually disappointing for both patients and physicians. Weight loss is difficult to achieve and even more difficult to sustain in the long term. When lifestyle modifications fail to achieve the predefined target, anti-obesity medications may be added on, as recommended by all relevant guidelines, including those of the Endocrine Society and recent guidelines for obese with diabetes. Glucagon-like peptide 1 (GLP-1) is an incretin secreted by L-cells in the intestinal mucosa and has been shown to act in the brain and periphery to cause effective weight loss. GLP-1 release is stimulated by food intake and its agonist, exenatide, is the first from the incretin family approved for weight-loss therapy by the Food and Drug Administration (FDA). In overweight and obese adults, it is concluded that the GLP-1 analogs and the Phentermine/Topiramate association proved to be among the best for the effects on weight reduction. Regarding childhood obesity, the FDA recently approved the use of Liraglutide. Schizophrenic patients, a target of studies due to risk factors, benefited from treatment with GLP-1 analogs.

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity

The incretin/glucagon system as a target for pharmacotherapy of obesity

GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications

Are GLP-1R agonists the long-sought-after panacea for obesity?

GLP-1 and Amylin in the Treatment of Obesity

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity

Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update

Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review

Future directions in obesity pharmacotherapy

Why does GLP‐1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP‐1 agonist alone in obese adults without type 2 diabetes?

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus

Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions

Synergistic Combinations of Gut- and Pancreas-Hormone-Based Therapies: Advancements in Treatments for Metabolic Diseases

New insights into the treatment of obesity.

Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss